Compare GECC & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GECC | GANX |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.8M | 78.2M |
| IPO Year | N/A | 2021 |
| Metric | GECC | GANX |
|---|---|---|
| Price | $5.55 | $1.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $10.75 | $7.50 |
| AVG Volume (30 Days) | 57.3K | ★ 532.0K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 21.62% | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | $0.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $1.41 |
| 52 Week High | $11.45 | $4.34 |
| Indicator | GECC | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 47.16 |
| Support Level | $4.85 | $1.66 |
| Resistance Level | $7.07 | $2.11 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 78.26 | 51.09 |
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.